Abstract
During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Current Enzyme Inhibition
Title: Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling
Volume: 6 Issue: 2
Author(s): Andrew Leask
Affiliation:
Keywords: PDGF, TGFβ, endothelin, rac, PPARγ, PKCε
Abstract: During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Export Options
About this article
Cite this article as:
Leask Andrew, Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791232999
DOI https://dx.doi.org/10.2174/157340810791232999 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cough in Respiratory and Autoimmune Disorders
Current Respiratory Medicine Reviews Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Role of Oxidative Stresses Induced by Diesel Exhaust Particles in Airway Inflammation, Allergy and Asthma: Their Potential as a Target of Chemoprevention
Inflammation & Allergy - Drug Targets (Discontinued) Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Two Different Functions of Doxycycline Which is Both An Antimicrobial Agent and An Immune Modulator
Anti-Infective Agents in Medicinal Chemistry Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Current Stem Cell Research & Therapy Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Targeting Serine Proteases in Asthma
Current Topics in Medicinal Chemistry Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Mouse Models of Primary Biliary Cirrhosis
Current Pharmaceutical Design Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Small RNAs Play Big Roles: MicroRNAs in Diabetic Wound Healing
Current Molecular Medicine Editorial (Thematic Issue: Vascular Damage In Systemic Sclerosis)
Current Rheumatology Reviews Radiolabeled Compounds in Diagnosis of Infectious and Inflammatory Disease
Current Pharmaceutical Design Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Inhibition of Geranyl-Geranyl Prenylation by Statins: A Novel Model of Disease Modification of Systemic Sclerosis
Letters in Drug Design & Discovery Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry